Amphetamines and psychosis

  • I. Munkvad
  • A. Randrup
  • R. Fog

Abstract

At the present stage of knowledge it seems reasonable to assume that every normal thought process or normal behaviour has one neuro-biological correlate, and that every abnormal form of function—even if induced by the environment—has another. The neurobiological correlate of schizophrenia has been the object of much speculation and research, and during the last fifteen years interesting information, summarized in the dopamine hypothesis, has emerged, mainly from studies with amphetamines and neuroleptic drugs. These drugs have, respectively, a psychotogenic and an anti-psychotic effect, both of which appear to be mediated mainly via actions on brain dopamine. Many new details about brain dopamine have been discovered recently, including information about the dopamine receptors and about the interactions of dopamine with other substances in the brain, i.e. with γ-aminobutyric acid (GABA) and with endorphins. These findings raise hopes that new anti-psychotic drugs can be created, including the ideal anti-schizophrenic drug, one which would not only antagonize psychotic behaviour but also bring about its replacement by normal behaviour.

Keywords

Placebo Depression Dopamine Schizophrenia Morphine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen, H., Braestrup, C. and Randrup, A. (1975). Apomorphine-induced stereotyped biting in the tortoise in relation to dopaminergic mechanisms. Brain. Behav. Ev. 11, 365CrossRefGoogle Scholar
  2. Christensen, A. V. (1979). Adaptation i dopamin neuroner efter enkel og gentagen dosering med neuroleptika. Thesis. The Royal Danish School of Pharmacy. CopenhagenGoogle Scholar
  3. Fog, R., Randrup, A. and Munkvad, I. (1967). Dependence of the amphetamine excitatory response upon amines in the corpus striatum. IVth World Congress of Psychiatry, Madrid. Excerpta Medica International Congress Series, no. 117Google Scholar
  4. Hecht, A. (1979). Behavioural effects produced by long-term administration of a neuroleptic drug (flupenthixol) upon social interaction in a group of eight rats. Psychopharmacology. 62. 301PubMedCrossRefGoogle Scholar
  5. Hyttel, J. (1979). Neurochemical effects of neuroleptic drugs. Thesis. University of CopenhagenGoogle Scholar
  6. Jørgensen, A., Fog, R. and Veilis, B. (1979). Synthetic enkephalin analogue in treatment of schizophrenia. Lancet, 1, 935PubMedCrossRefGoogle Scholar
  7. Kebabian, J. W. and Calne, D. B. (1979). Multiple receptors for dopamine. Nature. 277. 93PubMedCrossRefGoogle Scholar
  8. Krogsgaard-Larsen, P., Scheel-Krüger, J. and Kofod, H. (eds.) (1979). GABA-Neurotransmitters. (Copenhagen: Munksgaard; New York: Academic Press)Google Scholar
  9. Lehmann, H., Nair, N. P. V. and Kline. N. V. (1979). β-endorphin and naxolone in psychiatric patients: clinical and biological effects. Am. J. Psychiatry . 136. 762Google Scholar
  10. Lewander, T. (1977). Effects of amphetamine in animals. In R. Martin (ed.). Drug Addiction. vol. 2, pp. 33–46. (Berlin: Springer)Google Scholar
  11. Matthysse, S. W. (1977). The role of dopamine in schizophrenia. In E. Usdin. D. A. Hamberg and J. D. Barchas (eds.). Neuroregulators and Psychiatric Disorders. pp. 3–13. (New York: Oxford University Press)Google Scholar
  12. Meites, J., Bruni, J. F.. van Vugt, D. A. and Smith. A. F. (1979). Relation of endogenous opioid peptides and morphine to neuroendocrine functions. Life Sci., 24, 1325PubMedCrossRefGoogle Scholar
  13. Murphy, D. L. (1977). Animal models for mania. In I. Hanin and E. Usdin (eds.). Animal Models in Psychiatry and Neurology, pp. 211–223. (Oxford: Pergamon Press)Google Scholar
  14. Nielsen, E. B. (1977). Long-term behavioural and biochemical effects following prolonged treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology . 54. 203PubMedCrossRefGoogle Scholar
  15. Nielsen, M., Nielsen, E. B.. Ellison. G. and Braestrup. C. (1979). Modification of dopamine receptors in brain by continuous amphetamine administration to rats. In C. Ballus (ed.). Proceedings of 2nd World Congress o f Biol. Psychiat.. Barcelona 1978Google Scholar
  16. Randrup, A. and Mogilnicka. E. (1976). Spectrum of pharmacological actions on brain dopamine. Indications for development of new psychoactive drugs. Pol. J. Pharmacol. Pharm.. 28. 551PubMedGoogle Scholar
  17. Randrup. A.. Kjellberg, B.. Schiørring. E.. Scheel-Krüger. J.. Fog. R. and Munkvad. I. (1980). Stereotypies and their relevance for testing neuroleptics. In F. Hoffmeister and G. Stille (eds.). Antipsychotics and Antidepressants. (Heidelberg: Springer). (In press)Google Scholar
  18. Randrup, A. and Munkvad, I. (1974). Evidence indicating an association between schizophrenia and dopaminergic hyperactivity in the brain. In R. Cancro (ed.). Annual Review of the Schizophrenic Syndrome, vol. 3, pp. 130–136. (New York: Brunner/Mazel)Google Scholar
  19. Randrup, A. and Munkvad, I. (1968). Behavioural stereotypies induced by pharmacological agents. Pharmakopsychiatrie Neuro-Psychopharmakologie. 1. 18Google Scholar
  20. Randrup, A. and Munkvad. I. (1967a). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia (Berl.). 11. 300CrossRefGoogle Scholar
  21. Randrup, A. and Munkvad. I. (1967b). Stereotype behaviour produced by amphetamine and other substances. Investigations on the mechanism of action. In Proceedings of the Vth International Congress of the Collegium Internationale Neuropsychopharmacologicum. Excerpta Medica International Congress Series, no. 129Google Scholar
  22. Randrup, A., Munkvad, I., Fog, R. and Ayhan. I. H. (1975a). Catecholamines in activation, stereotypy, and level of mood. In A. J. Friedhoff (ed.).Catecholamines and Behaviour, vol. 1. pp. 89–107. (New York: Plenum Press)Google Scholar
  23. Randrup, A., Munkvad, I., Fog. R.. Braestrup. C. and Molander. L. (1979). The case for involvement of dopamine in depression and mania. Presented at the 11th C.I.N.P. Congress. July 9–14, Vienna. (Oxford: Pergamon Press)Google Scholar
  24. Randrup, A., Munkvad, I., Fog, R., Gerlach, J., Molander, L., Kjellberg, B. and Scheel-Krüger, J. (1975b). In W. B. Essman and L. Valzelli (eds.).Current Developments in Psychopharmacology, vol. 2, pp. 205–248. (New York: Spectrum)Google Scholar
  25. Randrup, A., Munkvad. I., Fog, V., Kjellberg, B., Lyon. M., Nielsen. E., Svennild. I. and Schiørring, E. (1976). Behavioural correlates to antipsychotic efficacy of neuroleptic drugs. In G. Sedvall, B. Uvnäs and Y. Zotterman (eds). International symposium onAntipsychotic Drugs, Pharmacodynamics and Pharmacokinetics. Stockholm, pp. 33–41. (Oxford: Pergamon Press)Google Scholar
  26. Scheel-Krüger, J. and Christensen, A. V. (1979). The role of GABA in acute and chronic neuroleptic action. Presented at the international symposium on Advances in Psvchopharmacology, Monte Carlo. (New York: Raven Press). (In press)Google Scholar
  27. Scheel-Krüger, J., Christensen, A. V. and Arnt, J. (1978). Muscimol differentially facilitates stereotypy but antagonizes motility induced by dopaminergic drugs: a complex GABA-dopamine interaction. Life Sei. , 22. 75CrossRefGoogle Scholar
  28. Schiørring, E. and Randrup, A. (1971). Social isolation and changes in the formation of groups induced by amphetamine in an open-field test with rats. Pharmakopsychiatrie Neuro-Psychopharmakologie, 4, 2Google Scholar
  29. Segal, D. S. and Janowsky, D. S. (1978). Psychostimulant-induced behavioural effects: possible models of schizophrenia. In M. A. Lipton, A. Dascio and K. F. Kilian (eds.). Psychopharmacology: a Generation of Progress, pp. 1113–1123. (New York: Raven Press)Google Scholar
  30. Seiden, L. S. and Dykstra. L. A. (1977). Psychopharmacology. A Biochemical and Behavioural Approach. (New York: Van Nostrand Reinhold)Google Scholar
  31. Sharman, D. F. (1978). Brain dopamine metabolism and behavioural problems of farm animals. In P. J. Roberts. G. N. Woodruff and L. L. Iversen (eds.). Advances in Biochemical Psychopharmacology, vol. 19. pp. 249–254. (New York: Raven Press)Google Scholar
  32. Tamminga, C. A., Crayton, J. W. and Chase. T. N. (1978). Muscimol: GABA agonist therapy in schizophrenia. Am. J. Psychiat., 135. 6Google Scholar
  33. de Wied, D. (1979). Schizophrenia as an inborn error in the degradation of bêta-endorphine: an hypothesis. Trends Neurosci .. 2. 79CrossRefGoogle Scholar

Copyright information

© MTP Press Limited 1980

Authors and Affiliations

  • I. Munkvad
    • 1
  • A. Randrup
  • R. Fog
  1. 1.Dept. E.Sct. Hans HospitalRoskildeDenmark

Personalised recommendations